In clinical trials of patients with GIST, treatment with either sunitinib (both at 50 mg/day on Schedule 4/2 and at 37.5 mg on the CDD schedule) or imatinib was found to be highly efficacious, suggesting that KIT inhibition was critical for tumor control [32-34]. The gene discussed is KIT; the disease is neoplasm.